Version 1
: Received: 12 March 2024 / Approved: 12 March 2024 / Online: 12 March 2024 (14:32:02 CET)
How to cite:
Katayama, M.; Uemura, Y.; Katori, D. Effect of Nucleic Acid Analog Administration on Fluctuations of Albumin to Globulin Ratio in Cats with Feline Infectious Peritonitis. Preprints2024, 2024030709. https://doi.org/10.20944/preprints202403.0709.v1
Katayama, M.; Uemura, Y.; Katori, D. Effect of Nucleic Acid Analog Administration on Fluctuations of Albumin to Globulin Ratio in Cats with Feline Infectious Peritonitis. Preprints 2024, 2024030709. https://doi.org/10.20944/preprints202403.0709.v1
Katayama, M.; Uemura, Y.; Katori, D. Effect of Nucleic Acid Analog Administration on Fluctuations of Albumin to Globulin Ratio in Cats with Feline Infectious Peritonitis. Preprints2024, 2024030709. https://doi.org/10.20944/preprints202403.0709.v1
APA Style
Katayama, M., Uemura, Y., & Katori, D. (2024). Effect of Nucleic Acid Analog Administration on Fluctuations of Albumin to Globulin Ratio in Cats with Feline Infectious Peritonitis. Preprints. https://doi.org/10.20944/preprints202403.0709.v1
Chicago/Turabian Style
Katayama, M., Yukina Uemura and Daichi Katori. 2024 "Effect of Nucleic Acid Analog Administration on Fluctuations of Albumin to Globulin Ratio in Cats with Feline Infectious Peritonitis" Preprints. https://doi.org/10.20944/preprints202403.0709.v1
Abstract
Background: Feline infectious peritonitis (FIP) is a fatal feline disease classified as either effusive (‘wet’), non-effusive (‘dry’), or a mixture of both forms (‘mixed’). The anti-FIP therapeutic effect of Mutian and molnupiravir, two drugs whose active ingredient is a nucleic acid analog, has been confirmed recently. Methods: Of the cats with FIP, we observed a total of 122 and 56 cases achieved remission after administration of Mutian and molnupiravir as routine treatments, respectively. Changes in clinical indicators suggested to be correlated with FIP remission (weight, hematocrit, and albumin to globulin ratio) before and after the administration of each drug and during follow-up observation were statistically compared for each FIP type. Results: In all three FIP types, administration of either Mutian or molnupiravir resulted in statistically significant increases in these indicators. Furthermore, the effect of Mutian on improving the albumin to globulin ratio was not observed at all in wet FIP, as compared with that of molnupiravir, but statistically significant in mixed and dry (P<0.02 and P<0.003, respectively). These clinical features were all due to differences in fluctuations of circulating globulin levels. Conclusions: These results indicate slight inflammatory responses might be elicited continuously by residual feline coronavirus non-disappeared through molnupiravir treatments.
Keywords
cat; feline infectious peritonitis; non-effusive; nucleic acid analog; albumin to globulin ratio; feline coronavirus; routine treatment
Subject
Medicine and Pharmacology, Veterinary Medicine
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
The commenter has declared there is no conflict of interests.
Comment:
This paper presents several significant issues. First, the drug Mutian, which was compared with molnupiravir, is mistakenly referred to by the manufacturer's name instead of the actual drug name. Additionally, there is no linked source for the information about the GS441524 content, and the claim that 100mg of Xraphconn contains 5mg of GS441524 is based on outdated or incorrect information.
Next, there are problems with the method of administering molnupiravir to cats. The pharmaceutical company does not recommend administering this drug as a suspension. Due to the use of a non-recommended method, the significant differences observed in the dry form cannot conclusively be attributed to molnupiravir itself.
Furthermore, the paper does not address the cats that died during the study.
It is unclear whether the deaths were ignored or if there were no fatalities in either group. If it's the latter, that would be quite remarkable.
Additionally, there are errors in the citation of references.
Ultimately, this paper should be subjected to peer review by an independent third party. Without such a review, its findings cannot be taken seriously.
Commenter:
The commenter has declared there is no conflict of interests.
Next, there are problems with the method of administering molnupiravir to cats. The pharmaceutical company does not recommend administering this drug as a suspension. Due to the use of a non-recommended method, the significant differences observed in the dry form cannot conclusively be attributed to molnupiravir itself.
Furthermore, the paper does not address the cats that died during the study.
It is unclear whether the deaths were ignored or if there were no fatalities in either group. If it's the latter, that would be quite remarkable.
Additionally, there are errors in the citation of references.
Ultimately, this paper should be subjected to peer review by an independent third party. Without such a review, its findings cannot be taken seriously.